Clinical trials: CRPC
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
- Trial name
- TRITON2 (NCT02952534)
- Testing
- Rucaparib
- Where
- 149 sites in United States, Australia and 10 more
- Volunteers
- 277 people
- Sponsor
- pharmaand GmbH
Castration Resistant Prostate Cancer
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
This is a single-institution, single-arm, open-label Phase 2 trial evaluating evofosfamide in subjects with M1 CRPC who fail first-line ARSIs.
- Trial name
- EVO (NCT06836726)
- Testing
- Evofosfamide
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids.
- Trial name
- NCT01685268
- Testing
- AT13387, abiraterone acetate, Prednisone
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 49 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Solid Tumor Cancer, Castration Resistant Prostate Cancer
Imaging of Solid Tumors Using DLL3 SPECT
This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors.
- Conditions
- Solid Tumor Cancer, Castration Resistant Prostate Cancer, Castration Resistant Prostate Cancer (CRPC), Neuroendocrine (NE) Tumors
- Trial name
- NCT07052760
- Testing
- 111In-ABD147, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT)
- Sponsor
- Thomas Hope
Prostate Cancer
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
This is a Phase Ib, open label study of ARN-509 administered in combination with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT01792687
- Testing
- ARN-509, Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer Metastatic
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The aim of the study is to assess the clinical utility of 18F-fluoro-deoxyglucose Positron Emission Tomography (PET)/Computed Tomography (CT) and Whole Body Magnetic Resonance Imaging (MRI) versus conventional bone scan and…
- Trial name
- NCT02814968
- Testing
- Enzalutamide, 18-FDG PET/CT, Whole body MRI
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- The European Uro-Oncology Group
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Prostate Cancer, Castration Resistant Prostate Cancer
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer
The main purpose of this study to define the good and/or bad effects of the combination of enzalutamide and CC-115 in patients with castration-resistant prostate cancer.
- Trial name
- NCT02833883
- Testing
- Enzalutamide, CC-115
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasms
Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms
To determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs…
- Trial name
- ERA 223 (NCT02043678)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Abiraterone, Prednisone/Prednisolone
- Where
- 163 sites in United States, Australia and 17 more
- Volunteers
- 806 people
- Sponsor
- Bayer
Prostate Cancer
Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00976755
- Testing
- everolimus
- Where
- 13 sites in Switzerland
- Volunteers
- 37 people
- Sponsor
- Swiss Cancer Institute
Castration Resistant Prostate Cancer (CRPC)
A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC
This is a prospective observational study to evaluate effectiveness and safety of Enzalutamide for Castration Resistant Prostate Cancer (CRPC) patients who decided to administer Enzalutamide after anti-androgen therapy.
- Trial name
- DELC (NCT02669147)
- Volunteers
- 160 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Castration-resistant Prostate Cancer
Oral Calcitriol With Ketoconazole in CRPC
The aim of this study is to estimate the PSA response rate with the use of ketoconazole (400mg QD + hydrocortisone 20mg AM, 10 mg PM) among men with CRPC in whom disease has progressed despite abiraterone
- Trial name
- NCT03261336
- Testing
- Calcitriol, Ketoconazole, Hydrocortisone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Donald Trump, MD
Prostate Cancer
Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer
This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to…
- Trial name
- Doce/Enza (NCT02685267)
- Testing
- Docetaxel, Enzalutamide, Prednisone
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Prostate Cancer Clinical Trials Consortium
Metastatic Castration-resistant Prostate Cancer (CRPC)
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
- Trial name
- NCT06249750
- Testing
- Immunotherapy, Targeted therapy, Hyperthermia
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pengyuan Liu
Castrate Resistant Prostate Cancer With Bone Metastasis
Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC
Studies objectives: To evaluate the safety, tolerability and efficacy of ACC given in combination with ZA or with Denosumab as compared to placebo given with ZA or with Denosumab as outline below: Safety and Tolerability: Adverse…
- Trial name
- NCT02864784
- Testing
- Amorphous calcium carbonate
- Where
- Israel
- Sponsor
- Amorphical Ltd.
Prostate Cancer
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients.
- Trial name
- ARMOR2 (NCT01709734)
- Testing
- galeterone
- Where
- 23 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- LTN PHARMACEUTICALS, INC.
Metastatic Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
- Trial name
- NCT05413421
- Testing
- ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- ORIC Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components.
- Trial name
- TLH-202 (NCT00684970)
- Testing
- Hamsa-1™ TL-118
- Where
- 5 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Tiltan Pharma Ltd.
PSMA PET-Positive Castration-Resistant Prostate Cancer
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225).
- Trial name
- NCT06549465
- Testing
- In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Convergent Therapeutics